MTMine Durusu Tanriover

Mine Durusu Tanriover

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mine Durusu Tanriover has a total of 321 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adverse Events in Following Immunization with Inactivated SARS-CoV-2 Vaccines (TURKOVAC and CoronaVac) in PCR-Positive Asymptomatic or Mildly Symptomatic Individuals Compared to PCR-Negative Recipients

    by Ateş Kara, İhsan Ateş, Sebahat Tekcan, Seçil Uysal, Yüksel Hakan Aydoğmuş, Mine Durusu Tanrıöver, Aykut Özdarendeli, Erdogan Oz, Muhammed Emin Demirkol

    Background/Objectives: COVID-19 vaccines may be given without requiring a negative test or absence of symptoms; however, this recommendation needs further safety evaluation. This study aimed to compare the adverse events following immunization (AEFI) between PCR-positive (asymptomatic/mildly symptomatic) and PCR-negative individuals at the time of vaccination, with a secondary objective of comparing the two vaccines (TURKOVAC and CoronaVac). Methods: This descriptive study was a secondary analysis of phase III clinical trials. Individuals who were positive for SARS-CoV-2 PCR at the time of vaccination constituted the PCR(+) group and those who tested negative or became positive after the 4th day following vaccination constituted the PCR(−) group. Whether participants had a history of COVID-19 was not considered. Results: Data from 5207 individuals were analyzed. AEFIs were more frequent in the PCR(+) group than PCR(−) group: site pain (24.5% vs. 16.7%, p < 0.001), arm pain (9.5% vs. 7.8%, p = 0.008), headache (14.8% vs. 10.0%, p < 0.001), fatigue (14.5% vs. 8.9%, p < 0.001), myalgia (12.3% vs. 7.5%, p < 0.001), sore throat (11.9% vs. 8.1%, p < 0.001), cough (7.9%; 11.1% vs. 6.9%, p < 0.001). These AEFIs were more frequent in the PCR(+) group with both vaccine groups separately. The distribution of AEFIs over time followed similar patterns in PCR(+) and PCR(−) individuals. Local AEFIs were slightly more common with the TURKOVAC, systemic AEFIs with the CoronaVac. Conclusions: While AEFIs were more common among PCR(+) group, they were mild, tolerable, and easily manageable. Our results support the suggestion that routine PCR testing prior to vaccination may not be warranted solely to mitigate concerns about anticipated adverse events.

  • Open Access

    Immunological insights into why pertussis continues to be endemic

    by Mine Durusu Tanriover, Kevin Forsyth, Qiushui He, Dimitri A. Diavatopoulos, Rodrigo Orozco Fernández, Daniela Flavia Hozbor, Donald B. Middleton, Rudzani Muloiwa, Flor M. Muñoz, Anna Ong-Lim, et al.

    Pertussis (whooping cough) is a vaccine-preventable bacterial disease caused by Bordetella pertussis. Despite widespread vaccination, cases have increased globally since the 1990s, with notable outbreaks in 2012, 2016, and following the COVID-19 pandemic. Persistent endemicity and periodic epidemics are driven by limited prevention of nasal colonization, waning immunity after vaccination or natural infection, and pathogen adaptation. Differences between acellular (aP) and whole-cell (wP) vaccines reflect distinct immune profiles, with aP vaccines favoring Th2 responses and wP vaccines inducing Th1/Th17 responses and tissue-resident memory T cells. Circulating strains have evolved under vaccine pressure, including shifts in ptxP, ptxA and prn alleles, increasing pertussis toxin production, emergence of pertactin-deficient variants, and rising macrolide resistance linked to 23S rRNA mutations. Optimizing current vaccine strategies and developing next-generation vaccines that improve durable, Th1/Th17-polarized immunity and reduce transmission are essential for enhanced pertussis control.

  • Open Access

    Older adults bear the burden: risk factors for severe influenza outcomes among hospitalized adults in a 9-season multicenter active surveillance study

    by Lale Ozisik, Mine Durusu Tanriover, Murat Ozdede, Ayse Tulay Bagci Bosi, Banu Cakir, Selim Badur, Joan Puig-Barberà, Meral Akcay, Serhat Unal

    Seasonal influenza causes substantial morbidity and mortality worldwide, yet local multi-season data from middle income settings remain limited. This study aimed to assess the clinical burden of influenza hospitalization and identify the independent predictors of severe outcomes in adults in Türkiye. A multicenter active surveillance study was conducted across Global Influenza Hospital Surveillance Network sites in Türkiye over 9 influenza seasons (2012–2024). Patients screened within 72 hours of hospital admission with symptoms of influenza-like illness were included. Only adults with laboratory-confirmed influenza infection using real-time reverse transcription polymerase chain reaction were included in the risk analysis. Multivariate logistic regression was performed to identify independent risk factors for intensive care unit (ICU) admission, mechanical ventilation (MV), and in-hospital mortality. Among 2439 hospitalized adults; 351 had laboratory-confirmed influenza, of whom 85.2% had at least 2 chronic condition. Severe outcomes were frequent: 21.1% required intensive care, 21.1% required MV, and 11.1% died. Of those who died in the hospital, 69.2% were 65 years and older. Each additional year of age increased the odds of ICU admission by 3% and in-hospital death by 2%. Diabetes increased ICU admission risk (adjusted odds ratio [aOR] 1.91, 1.09–3.33). Chronic obstructive pulmonary disease was the only independent predictor of MV (aOR 3.13, 1.77–5.61). Patients with chronic kidney disease had a more than fourfold increased risk of in-hospital mortality (aOR 4.54, 2.05–9.88) and malignancy (aOR 3.75, 1.63–8.38) were another strongest determinant of mortality. Influenza vaccination reduced the risk of ICU admission by 66% (aOR 0.34, 0.12–0.80). These findings highlight the considerable burden of influenza among older adults and those with chronic conditions, reinforcing the need for enhanced vaccination strategies and timely antiviral treatment for this population.

  • Open Access

    Combined low-volume high-intensity interval training and inspiratory muscle training in patients with metabolic syndrome: A randomized controlled trial

    by Hilal Uyar, Naciye Vardar-Yagli, Melda Saglam, Ebru Calik, Oguz Abdullah Uyaroglu, Murat Ozdede, Mine Durusu Tanriover

    Background: Low-volume high-intensity interval training (LVHIIT) is known to improve cardiometabolic health; however, the potential additive effects of combining LVHIIT with inspiratory muscle training (IMT) in reducing the severity of metabolic syndrome (MetS) have not been fully explored. This study aimed to evaluate the effects of 8 weeks of IMT combined with LVHIIT on cardiorespiratory fitness, MetS parameters, and respiratory muscle function in individuals with MetS. Methods: This randomized, controlled, double-blind trial included 38 adults with MetS, aged 42 to 60 years, who were randomly assigned to 3 groups: LVHIIT (n = 12), LVHIIT + IMT (n = 14), and control (n = 12). The primary outcome was the change in maximal oxygen consumption (VO 2 max) after 8 weeks. Secondary outcomes included MetS z -score, anthropometric measures, metabolic blood markers, and respiratory muscle strength and endurance. All outcomes were assessed at baseline and after the 8-week intervention. Results: The mean age of participants was 50 ± 5 years, and 67% were women. Significant group × time interactions were observed for VO 2 max, oxygen uptake efficiency slope, heart rate recovery at 1 minute, waist circumference, hip circumference, visceral fat ratio, fasting plasma glucose, glycosylated hemoglobin A1c, and MetS z -score ( P < .05). Both LVHIIT and LVHIIT + IMT groups showed significant improvements in VO 2 max ( P < .001). Respiratory muscle strength and endurance increased significantly only in the LVHIIT + IMT group ( P < .001). Conclusion: Eight weeks of LVHIIT combined with IMT led to improvements in cardiorespiratory fitness, respiratory muscle function, and key MetS components, including MetS z -score. Integrating IMT into LVHIIT may be an effective, clinically feasible, and time-efficient approach to improve cardiometabolic health in individuals with MetS in cardiac rehabilitation.

  • Open Access

    Barriers and Opportunities to Include Underrepresented Population Groups in Vaccine Trials: Cross-Sectional, Observational, Online Survey Study From the VACCELERATE Research Network

    by Mine Durusu Tanriover, Dimitrios Poulimeneas, Grammatiki-Christina Tsopela, Ioannis Kopsidas, Christos Argyropoulos, Romina Di Marzo, Olena Valdenmaiier, Stine Finne Jakobsen, Paula Valle Simon, Antonio Javier Carcas-Sansuan, et al.

    Background: Despite the vast growth of vaccine studies during the SARS-CoV-2 pandemic, clinical trials failed to adequately represent diverse societal groups, resulting in the underrepresentation of specific populations. Understanding the factors hampering participation in vaccine clinical trials is essential to better identify structural, ethical, and communication barriers and to improve inclusive strategies for broader and more equitable participation in future vaccine research. Objective: This study aimed to identify the perceived barriers to participation in vaccine trials among pregnant and lactating women, children aged younger than 18 years, and adults aged older than 65 years, as reported by professionals with expertise in vaccines or vaccine trials. Methods: An online questionnaire was developed to gather personal information, group-specific barriers to vaccine trial participation, and suggestions to overcome these barriers. Data are presented as absolute (n/N) and relative frequencies (%). Results: A total of 115 respondents, the majority (n=73, 63.5%) of whom were working in the scientific community, completed the online survey. Challenges in recruiting children were identified due to “safety or efficacy concerns,” “difficulties about ethics and regulatory issues,” and “lack of targeted information and communication.” Challenges in recruiting pregnant and lactating women were primarily “ethics and regulatory requirements,” “safety issues,” and “lack of prioritization or interest.” “Lack of information and communication channels adapted to the specific target group,” along with “lack of prioritization,” were the main challenges in recruiting older participants. Provision of health-related incentives, including but not limited to access to new treatments and receiving expert medical care, seems to be the top-rated motivation to participate in vaccine clinical trials. Conclusions: The main challenges in recruiting pregnant and lactating women and children in vaccine trials involve safety and efficacy concerns, as well as lengthy ethical and regulatory processes. For older adults, key issues include poor communication channels tailored to their needs, limited information, lack of prioritization, funding, infrastructure, and industry interest. Across all underrepresented groups, low awareness of and poor communication about research opportunities were major barriers. Additionally, mobility issues affected older adults, while lack of motivation and incentives affected children, and low health literacy and provider uncertainty impacted pregnant and lactating women. Improving communication infrastructure and enhancing communication strategies with clear, tailored messages to build trust and motivate participation are essential to improve inclusion in vaccine research.


  • Open Access

    The Ongoing Challenge of Pertussis in Eastern and Northern Europe: Recommendations from the Global Pertussis Initiative

    by Mine Durusu Tanriover, Ulrich Heininger, Ergin Çiftçi, Anca Cristina Drăgănescu, Andrzej Fal, Maria Tsolia, Dace Zavadska, Rodrigo Orozco Fernández, Daniela Flavia Hozbor, Donald B. Middleton, et al.

    Pertussis (whooping cough), a vaccine-preventable disease that affects people of any age, has resurged globally after the COVID-19 pandemic. Key reasons for recent pertussis outbreaks include suboptimal pertussis vaccination coverage (particularly for vaccination during pregnancy) and growing vaccination hesitancy. During the 2023-2024 pertussis outbreaks in Europe, adolescents aged 10-14 years and 15-19 years had the first and third highest incidence rates, respectively. To reduce pertussis burden, it is essential to strengthen vaccination programs in the indicated target groups. This requires increased awareness among healthcare professionals about the local epidemiology of pertussis and its clinical presentation, alongside reinforcement of the benefits of vaccination for disease prevention. In parallel, robust surveillance systems and strong public health capacity for early disease detection and response are crucial to effectively manage outbreaks and build resilience against future outbreaks. Infants remain at high risk for pertussis, with complications, hospitalisation, and death being more common than in other age groups. Immunisation programmes combining vaccination during pregnancy, to protect newborn infants until their primary immunisation series has induced immunity, and infant immunisation are key to reducing morbidity and mortality. Strategies to improve pertussis vaccination uptake among adolescents and adults, especially those with high-risk medical conditions, are also essential. Strengthening global collaborations to invest in and build surveillance systems capable of identifying and responding to future outbreaks, to align national policies, to scale up immunisation during pregnancy, and to adopt a life-long immunisation approach are needed to better control endemic pertussis and manage future outbreaks.


  • ECHO+ model: enhancing pharmaceutical care with integrated ecological outcomes

    by Izgi Bayraktar, Mine Durusu Tanriover, Aygin Bayraktar-Ekincioglu

  • Open Access

    Burden of Pneumococcal Disease and Adult Vaccination Landscape: An Overview with Data and Policy Insights from Türkiye

    by Mine Durusu-Tanrıöver

    Streptococcus pneumoniae (pneumococcus) is responsible for various non-invasive and invasive infections and remains a major source of morbidity and mortality, particularly among older adults and at-risk adults. Vaccination is an effective way to prevent pneumococcal disease, and pneumococcal vaccines have been part of national immunization programs for many years. While vaccination coverage is high in children, uptake among older adults and at-risk adult populations remains below desired levels. This article aimed to highlight the burden of pneumococcal disease in adults, review current pneumococcal vaccines, and present a comprehensive overview supported by data from Türkiye. Keywords: Adult, pneumococcal, vaccine